Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)

NCT03491683 is registered in ClinicalTrials.gov with Inovio Pharmaceuticals as lead sponsor.

NCT NCT03491683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03491683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
Lead sponsor
Inovio Pharmaceuticals
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 31, 2018
Completion date
December 31, 2026
Enrollment
52 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma